LeMaitre Vascular, Inc. LMAT R2KR3KPHARMA
Company Overview
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Why Investors Should Care
Generates a return on equity of 16.8%, reflecting efficient use of shareholder capital.
Net profit has compounded at 25.1% per year over the last five years.
Revenue has grown at a 10.4% CAGR over the past five years.
Maintains a net profit margin of 25.0%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $249.60M (+13.5% YoY); net profit $57.73M.
- Trailing 12 Months Year-on-year growth — revenue +9.6%, earnings +23.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.4%, profit CAGR 25.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.45% |
| 1 Year: | 9.60% |
Compounded Profit Growth
| 5 Years: | 25.13% |
| 1 Year: | 23.30% |
Stock Price Performance
| 1 Year: | -14.44% |
| 6 Months: | -24.30% |
| 3 Months: | -14.36% |
| 1 Month: | +0.11% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.16 · Neutral
P/E of 28.21 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 25.0%.
- Compounding revenue at 10.4% over 5 years.
- Profit CAGR of 25.1% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 30.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LMAT LeMaitre Vascular, Inc. R2KR3KPHARMA | 80.67 | 28.21 | $1.84B | 1.24% | 11.72% | 16.77% | 10.45% | 25.13% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 24.14M | 25.75M | 24.82M | - | 25.99M | 27.02M | 24.16M | - | 28.48M | 29.48M | 29.10M | - | 30.55M | 24.85M | 36.42M | - | 35.88M | 40.67M | 38.37M | - | 39.56M | 39.03M | 39.03M | - | 47.08M | 50.12M | 47.41M | - | 53.48M | 55.85M | 54.82M | - | 59.87M | 64.23M | 61.05M | 64.45M | 66.55M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.45M | 19.26M | 15.09M | 18.26M | 18.16M | - |
| Gross Profit | 17.02M | 16.19M | 17.35M | 17.52M | 17.58M | 18.25M | 18.47M | 18.99M | 17.25M | 19.22M | 19.46M | 20.32M | 20.17M | 19.91M | 20.48M | 17.03M | 22.70M | 24.40M | 23.80M | 26.76M | 24.87M | 25.96M | 25.96M | 27.81M | 25.07M | 26.05M | 30.88M | 32.09M | 30.82M | 33.27M | 36.66M | 38.47M | 37.18M | - | 41.42M | 44.97M | 45.95M | 46.19M | 48.40M | 50.76M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.79M | 28.83M | 25.64M | 27.36M | 30.62M | - |
| Operating Income | 5.34M | 3.91M | 4.19M | 5.54M | 5.05M | 6.32M | 4.86M | 11.54M | 4.61M | 7.19M | 4.43M | 5.92M | 5.91M | 4.93M | 4.35M | 4.87M | 10.02M | 9.54M | 7.95M | 11.11M | 9.07M | 8.30M | 7.93M | 5.78M | 6.15M | 6.97M | 7.87M | 9.45M | 9.18M | 10.21M | 11.87M | 14.38M | 13.15M | - | 12.63M | 16.14M | 20.31M | 18.83M | 17.77M | 20.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.08M | 22.02M | 26.48M | 24.20M | 23.59M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.29M | 1.30M | 1.30M | 1.30M | 1.30M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.24M | 18.07M | 22.57M | 20.30M | 19.67M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.23M | 4.29M | 5.21M | 4.72M | 3.99M | - |
| Net Income | 3.23M | 2.60M | 3.22M | 4.63M | 5.04M | 4.28M | 3.85M | 8.75M | 4.31M | 6.03M | 3.51M | 4.62M | 5.18M | 4.61M | 3.17M | 3.50M | 7.51M | 7.03M | 5.93M | 8.30M | 6.50M | 6.17M | 6.04M | 3.52M | 5.46M | 5.63M | 6.04M | 8.10M | 7.50M | 8.46M | 9.89M | 11.83M | 11.14M | - | 11.01M | 13.78M | 17.36M | 15.58M | 15.68M | 17.05M |
| Diluted EPS | 0.17 | 0.13 | 0.16 | 0.23 | 0.25 | 0.21 | 0.19 | 0.43 | 0.21 | 0.30 | 0.17 | 0.23 | 0.25 | 0.23 | 0.16 | 0.17 | 0.37 | 0.34 | 0.28 | 0.40 | 0.30 | 0.28 | 0.27 | 0.16 | 0.25 | 0.25 | 0.27 | 0.36 | 0.33 | 0.38 | 0.44 | 0.52 | 0.49 | - | 0.48 | 0.60 | 0.75 | 0.68 | 0.68 | 0.74 |
| R&D Expense | 1.54M | - | 1.66M | 1.63M | 1.76M | - | 1.82M | 1.99M | 2.04M | - | 2.24M | 2.26M | 2.28M | - | 2.99M | 2.14M | 2.10M | - | 2.84M | 2.65M | 2.85M | - | 2.93M | 3.35M | 3.46M | - | 3.88M | 4.52M | 4.22M | - | 4.09M | 4.28M | 3.66M | - | 4.09M | 3.54M | 2.97M | - | 4.06M | 4.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.91M | 56.06M | 57.69M | 56.73M | 64.55M | 71.10M | 78.35M | 89.15M | 100.87M | 105.57M | 117.23M | 129.37M | 154.42M | 161.65M | 193.48M | 219.86M | 249.60M |
| Gross Profit | 37.30M | 41.72M | 40.23M | 40.87M | 45.12M | 48.43M | 54.17M | 62.94M | 70.70M | 73.94M | 79.85M | 84.62M | 101.38M | 104.90M | 127.05M | 150.90M | 178.54M |
| Operating Income | 1.95M | 4.01M | 3.69M | 4.24M | 4.52M | 6.34M | 11.51M | 16.34M | 21.10M | 28.21M | 21.18M | 28.79M | 36.42M | 26.83M | 36.71M | 52.26M | 67.91M |
| Net Income | 1.60M | 6.01M | 2.14M | 2.57M | 3.20M | 3.92M | 7.76M | 10.59M | 17.18M | 22.94M | 17.93M | 21.22M | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Diluted EPS | 0.10 | 0.37 | 0.13 | 0.16 | 0.20 | 0.23 | 0.42 | 0.55 | 0.86 | 1.13 | 0.88 | 1.04 | 1.25 | 0.93 | 1.34 | 1.93 | 2.52 |
| R&D Expense | 5.91M | 5.49M | 4.42M | 5.09M | 5.24M | 4.67M | 5.48M | 6.14M | 6.64M | 8.20M | 9.28M | 10.10M | 11.80M | 13.29M | 16.97M | 15.65M | 14.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 63.27M | 59.69M | 63.06M | 70.49M | 81.49M | 90.70M | 101.92M | 126.32M | 153.09M | 188.34M | 252.81M | - | 310.48M | 346.78M | 551.82M | 615.69M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 161.73M | 194.60M | 402.19M | 468.23M |
| Cash & Equivalents | 15.89M | 23.19M | 22.61M | 20.13M | 16.45M | 14.71M | 18.69M | 27.45M | 24.29M | 19.10M | 26.32M | 11.79M | 26.76M | - | 19.13M | 24.27M | 25.61M | 28.24M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.28M | 52.33M | 55.94M | 58.25M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.04M | 25.06M | 30.06M | 33.61M |
| Total Liabilities | - | - | 10.92M | 7.60M | 10.17M | 13.93M | 13.29M | 12.82M | 14.42M | 16.55M | 22.85M | 40.20M | 80.24M | - | 42.27M | 48.88M | 214.53M | 222.17M |
| Current Liabilities | - | - | 10.39M | 6.54M | 8.39M | 10.22M | 10.04M | 10.37M | 10.48M | 13.19M | 19.76M | 20.85M | 25.14M | - | 25.33M | 29.88M | 30.61M | 36.32M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 167.77M | 168.65M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.60M | 19.09M | 185.69M | 185.59M |
| Total Equity | 45.75M | 48.21M | 52.36M | 52.09M | 52.89M | 56.56M | 68.21M | 77.88M | 87.50M | 109.77M | 130.24M | 148.14M | 172.57M | - | 268.20M | 297.90M | 337.29M | 393.52M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.66M | 23.91M | 24.15M | 24.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.44M | 7.05M | 3.17M | 4.72M | 5.39M | - | - | 16.90M | 22.87M | 19.51M | 14.18M | 34.80M | 35.10M | 25.38M | 36.75M | 44.12M | 81.25M |
| Investing Cash Flow | 2.18M | -5.24M | -1.82M | -5.20M | -6.19M | - | - | -17.21M | -28.96M | -7.05M | -24.10M | -52.89M | -61.08M | -10.37M | -24.71M | -200.12M | -64.94M |
| Financing Cash Flow | -376.00K | -2.33M | -3.80M | -3.16M | -961.00K | - | - | -2.58M | 80.00K | -4.42M | -4.62M | 32.16M | 13.70M | -9.23M | -7.13M | 158.10M | -14.54M |
| Capital Expenditure | -577.00K | -2.47M | -2.02M | -1.21M | -2.73M | -1.17M | -2.27M | -2.84M | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 4.86M | 4.58M | 1.15M | 3.51M | 2.65M | - | - | 14.05M | - | - | - | - | - | - | - | - | - |
| Share Buybacks | 686.00K | 2.52M | 2.21M | 2.02M | 373.00K | 211.00K | 266.00K | 311.00K | 778.00K | 741.00K | 683.00K | 570.00K | 802.00K | 642.00K | 853.00K | 1.72M | 1.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 73.3% | 74.4% | 69.7% | 72.0% | 69.9% | 68.1% | 69.1% | 70.6% | 70.1% | 70.0% | 68.1% | 65.4% | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
| Operating Margin % | 3.8% | 7.2% | 6.4% | 7.5% | 7.0% | 8.9% | 14.7% | 18.3% | 20.9% | 26.7% | 18.1% | 22.3% | 23.6% | 16.6% | 19.0% | 23.8% | 27.2% |
| Net Margin % | 3.1% | 10.7% | 3.7% | 4.5% | 5.0% | 5.5% | 9.9% | 11.9% | 17.0% | 21.7% | 15.3% | 16.4% | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
| ROE % | 3.3% | 11.5% | 4.1% | 4.9% | 5.7% | 5.7% | 10.0% | 12.1% | 15.6% | 17.6% | 12.1% | 12.3% | - | 7.7% | 10.1% | 13.1% | 14.7% |
| ROCE % | - | 7.6% | 6.9% | 7.8% | 7.5% | 8.9% | 14.3% | 17.9% | 18.7% | 21.2% | 12.6% | 12.6% | - | 9.4% | 11.6% | 10.0% | 11.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.31% | 3.27M | $263.31M |
| 2 | Conestoga Capital Advisors, LLC | 5.98% | 1.37M | $110.02M |
| 3 | First Trust Advisors LP | 4.78% | 1.09M | $87.97M |
| 4 | Congress Asset Management Co | 4.21% | 963.71K | $77.53M |
| 5 | Vanguard Capital Management LLC | 4.17% | 953.44K | $76.70M |
| 6 | State Street Corporation | 3.94% | 901.42K | $72.52M |
| 7 | Copeland Capital Management, LLC | 3.67% | 839.46K | $67.53M |
| 8 | Geode Capital Management, LLC | 3.45% | 788.84K | $63.46M |
| 9 | Price (T.Rowe) Associates Inc | 3.30% | 755.14K | $60.75M |
| 10 | Vanguard Portfolio Management LLC | 2.64% | 604.83K | $48.66M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LMAT
PAHC or LMAT: Which Is the Better Value Stock Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNYm56NzVpcllBZXZWZ1hIckxGd003S1FSS1B1NVVyMC11bHhhMlBSLWtLNVdwRnE1N2owc25VZEpETk84d0FTS3ktYmdvNDV0T25BT2U4SlpKblY1MzFWVnJjZVhSYk5nbVROZC01NDZZNEhZaG9YOE1PdE1FXzhwSm43ZG5jcGFtMGp4Mk…
Why LeMaitre (LMAT) Shares Are Getting Obliterated Today - StockStory
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPeThweVpnaHRvX1k1Vkk3OTB3TWNkVjR1R21sZER1MmF1ejBfWUhyX2xmVFlsbGN2SzBValZ3QWFsLWVjM3JZQkVfZDRoSm5TNk1VbWpHNnhXckxRT0NEenZqODhzNG1JQUt1WUtpZ2xkNkRqWnRQcXQ5ZkhnTHYwVk5OaHEtS1FUa1lURU…
LeMaitre Vascular (LMAT) Pullback Puts Its Valuation Narrative Back In Focus - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOeFhOQVhnRC1uTVA1eGFDX1V4bDRCMUVkOV9VY0NOMF90THVzdUlsczNuUUx3d283OHhpVVI2aHJEWHNQaEJBTkFwcGg1MjA0eWlBRmxId2NBelRsOWNOTFc1NWN2UW1pMlBvN2hDUFVSYmJhRzQtLVRJZXBYQUFiME1OcDVWMHJ2S0lMNV…
Corient Private Wealth LP Purchases New Position in LeMaitre Vascular, Inc. $LMAT - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOQ0Y4MzZFN29BZGR1akN5VHB5TTROVF9faG9MNXJoVWljUVVzS0RlX2NSXzZ6Q1lGTzJ1cGtjX2RwMk9MZERHQndMdk96a21LU1p4UFJpcy1uODdiV1dNMGgxRzF6MDlValBFaU9aZVZBR1I4azBtZ0FYWmZyWmtmX2FqWmpzYkh3OG9yWk…
$LMAT stock is down 20% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQbDUtUV95VkE2ZmpLTVgyTk9JZFdIeldKQmwtUEhyclNkQ3Z2cTlRN2hIbm9OWFdUUmV6V1RUV2laN1VObFl2aEdrTlRZVTNRSmIyd0pwWU9VZE1wck9uV19CczZGQ2hyNnc2Ty1GOV9McDlTbUNvVVJhbnJVcm1DajVKX2ZkWDlqbm5Lan…
LeMaitre Vascular (LMAT) insider Bridget Ross files to sell 4,322 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPenhaX0Rwa3pCa1RXOW5Ec1BfYm5TTHFuWllHcGVVWHZnb3FmcloxeG5PTlppYUZPem85bHVGQi1XSzNmcDVfdk5CR0VJSTVRRzZVemhEbjNWMGtIcW9BUVF4WDBySTU2dFI3bkx1MWFDaDJTZXV6Sy1HX29zNTctYnE1TzhIX0d4bU12MT…
LMAT — Frequently Asked Questions
What is the current share price of LeMaitre Vascular, Inc. (LMAT)?
As of 2026-09-07 16:24 PDT, LeMaitre Vascular, Inc. (LMAT) trades at $80.67 on NasdaqGM. Its 52-week range is $78.76 to $116.75.
What is the market capitalisation of LMAT?
LeMaitre Vascular, Inc. (LMAT) has a market capitalisation of $1.84B on NasdaqGM.
What is the P/E ratio of LMAT?
LMAT trades at a trailing price-to-earnings (P/E) ratio of 28.21. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.58.
Does LMAT pay a dividend?
LeMaitre Vascular, Inc. (LMAT) currently offers a dividend yield of 1.24%.
What is the return on equity (ROE) of LMAT?
LMAT has a return on equity (ROE) of 16.77%. Its return on capital employed (ROCE) is 11.72%.
Is LMAT a good stock to buy?
This page provides a data-driven analysis of LeMaitre Vascular, Inc. (LMAT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.